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Human concentrative nucleoside transporter-1 (hCNT1)
(SLC28A1) is a widely expressed, high-affinity, pyrimi-
dine-preferring, nucleoside transporter implicated in the
uptake of naturally occurring pyrimidine nucleosides as
well as a variety of derivatives used in anticancer treat-
ment. Its putative role in the uptake of other pyrimidine
nucleoside analogues with antiviral properties has not
been studied in detail to date. Here, using a hCNT1 stably
transfected cell line and the two-electrode voltage-clamp
technique, we have assessed the interaction of selected
pyrimidine-based antiviral drugs, inhibitors of HIV-1
reverse transcriptase such as zidovudine (AZT), stavudine
(d4T), lamivudine (3TC) and zalcitabine (ddC), with hCNT1.
hCNT1 transports AZT and d4T with low affinity, whereas
3TC and ddC are not translocated, the latter being able to
bind the transporter protein. Selectivity appears to rely
mostly upon the presence of a hydroxyl group in the 3′-
position of the ribose ring. Thus, hCNT1 cannot be
considered a broad-selectivity pyrimidine nucleoside
carrier; in fact, very slight changes in substrate structure
provoke a dramatic shift in selectivity. 
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Among antiviral nucleoside-derived drugs, some of the
oldest in anti-HIV-1 therapy are pyrimidine nucleoside
derivatives for which the major routes responsible for
their transport into cells are not well understood. Three
isoforms of concentrative nucleoside transporters
(CNTs) (SLC28) have been identified. CNT1
(SLC28A1), which is a pyrimidine nucleoside-preferring
transporter, CNT2 (SLC28A2), a purine nucleoside-
preferring carrier protein and CNT3 (SLC28A3), a
broad-specificity nucleoside transporter protein  [1–4].
CNT1, as well as being responsible for the uptake of
naturally occurring pyrimidine nucleosides into cells,
is also a high-affinity transporter for a variety of
pyrimidine nucleoside-derived drugs used in anti-
cancer treatment, such as gemcitabine and the
capecitabine-derived metabolite 5′-DFUR [5–7].
Heterologous expression of human CNT1 (hCNT1) in
CHO-K1 cells results in increased sensitivity to 5′-
DFUR, even when the endogenous nucleoside trans-
port activity of this cell line, which is exclusively
accounted for by equilibrative nucleoside transporters
(ENTs), is pharmacologically inhibited [7]. Indeed,
expression of hCNT1 in cell lines derived from pancre-
atic adenocarcinomas similarly increased sensitivity to
gemcitabine [8]. These observations highlight the
important role that hCNT1 may play in chemosensi-
tivity to anticancer drugs and raises the question of
whether hCNT1 is similarly implicated in antiviral
drug uptake.
CNT1 is expressed in the apical domain of the
plasma membrane in intestinal and renal epithelial cells
[9–13]. Thus, CNT1 plays a role in absorption and
tubular re-uptake of pyrimidine nucleosides in the intes-
tine and kidney, respectively. In hepatocytes, CNT1 is
similarly located at the apical canalicular membrane
and is likely to contribute to nucleoside salvage from
bile [14]. CNT1 is also expressed in bone marrow
macrophages [15–17]. Macrophages rely upon salvage
pathways for nucleoside supply and indeed CNT1
activity and expression is highly regulated in this cell
type following cytokine-triggered activation [17].
Overall, CNT1 tissue distribution suggests a putative
role of this transporter protein in determining nucleo-
side-derived drug pharmacokinetics, particularly for
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antiviral nucleosides, which are administered orally.
Moreover, macrophages are also significant latent
reservoirs for HIV-1 during antiviral treatment [18]
and, consequently, changes in transporter expression
following macrophage activation may also contribute
to the modification of intracellular nucleoside-derived
drug bioavailability. 
In this study, we have addressed the question of
whether hCNT1, in addition to its high-affinity trans-
port of pyrimidine nucleoside derivatives used in
anticancer therapy, is also a candidate for mediating
the uptake of pyrimidine-based antiviral drugs. We
have used an hCNT1 stably transfected cell line and
the two-electrode voltage-clamp technique on Xenopus
laevis oocytes expressing the hCNT1 transporter, to
determine whether selected pyrimidine-based antiviral
drugs, such as zidovudine (AZT), stavudine (d4T),
lamivudine (3TC) and zalcitabine (ddC) do indeed
interact with hCNT1.
Materials and methods
Nucleosides, nucleoside-derived drugs and other
chemicals
Uridine ([5,6-3H], 35–50 Ci/mmol) was purchased
from Amersham Biosciences (Amersham, UK).
Cytidine ([5-3H(N)], 21.5 Ci/mmol) was from
Moravek Biochemicals (Calif., USA). Uridine, thymi-
dine, cytidine, 2′-deoxycytidine, AZT, d4T, ddC and
5′-DFUR were obtained from Sigma-Aldrich (Saint
Louis, Mo., USA). 3′-Deoxythymidine was purchased
from Fluka Chemie GmbH (Buchs, Switzerland). 3TC
was kindly donated by the Hospital Universitari
Germans Trias i Pujol (Badalona, Spain).
Cell culture and nucleoside uptake measurements
A CHO-K1 cell line (hCNT1-CHO) expressing the
human concentrative pyrimidine nucleoside trans-
porter, hCNT1, has been used. This clone was
generated as previously described [7] by stable trans-
fection of CHO-K1 cells with a pCDNA3 vector
incorporating a hCNT1 cDNA, cloned from human
foetal liver (GenBank accession number U62966).
hCNT1-CHO cells showed a typical hCNT1 activity
pattern, characterized by high-affinity uptake of
pyrimidine nucleosides and a lack of transport of
purine nucleosides [7]. Cells were routinely cultured in
Minimum Essential Medium (MEM)-Eagle supple-
mented with 4% (vol/vol) foetal bovine serum, 1 mM
sodium pyruvate, 2 mM L-glutamine and a mixture of
non-essential amino acids and antibiotics, as previ-
ously described [7]. 
hCNT1 activity was measured by incubating semi-
confluent cell monolayers for 90 sec (initial velocity
conditions) in an uptake buffer, supplemented with
either sodium or choline chloride, in which the labelled
pyrimidine nucleoside was added at a final concentra-
tion of 1 µM (specific activity 1 µCi/nmol). This
method allows the calculation of Na+-dependent
uptake rates that are exclusively accounted for by the
hCNT1 transporter. Incubations were stopped by rapid
aspiration of the uptake buffer followed by immediate
washing with a cold stop solution, as previously
described [19,20]. To assess whether a selected nucleo-
side interacts with the hCNT1 transporter protein,
Na+-dependent uridine uptake was monitored in the
presence of high concentrations of the putative
inhibitor. Once inhibition by a particular nucleoside-
derivative was observed, the substrate dependence of
this effect was further monitored by using increasing
concentrations of the inhibitor to determine IC50
values. The Cheng–Prusoff equation was then used,
when applicable, to calculate Ki values, as recently
described by De Koning and co-workers, when moni-
toring the substrate recognition motifs of nucleobase
transporters [21].
Expression of CNT1 in X. laevis oocytes and electro-
physiological recordings
The hCNT1 cDNA was subcloned into a Bluescript
vector, which was then linearized for cRNA synthesis,
as previously described [6]. X. laevis oocytes were
injected with 50 ng of cRNA. Oocytes were main-
tained at 18ºC in Barth’s medium for 3–5 days. The
transportability of the selected pyrimidine nucleosides
and nucleoside-derived drugs was then assessed, taking
advantage of the fact that hCNT1 function is associ-
ated with substrate-induced Na+ inward currents, using
the two-electrode voltage-clamp technique [22]. The
oocyte membrane potential (Vm) was held at –50 mV
for continuous current recordings using Axoscope
V1.1.1.14 software (Axon Instruments, Foster City,
Calif., USA). To determine the current/voltage relation-
ship, 11 pulses of potential between +50 and –150 mV
(–20 mV decrement) were applied for 100 ms using
pClamp 6 software (Axon Instruments). The apparent
affinity constant (K0.5) and the maximal current for
saturating substrate concentrations (Imax) were then
obtained by fitting the steady-state currents at each
membrane potential to the equation: I = Imax ·
[S]/(K0.5+[S]), where [S] is the substrate concentration,
using the non-linear fitting method in SigmaPlot 8
(SPSS, Inc., Chicago, Ill., USA).
Statistical analysis
The unpaired Student’s t-test has been used for the
statistical comparison of experimental data. This
analysis has been carried out using GraphPad Prism
4.0 software (GraphPad Software, Inc., San Diego,
Calif., USA).
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Results
The high-affinity interaction between the pyrimidine
nucleoside cytidine and hCNT1 was assessed in our
mammalian cell model by firstly monitoring cytidine
uptake kinetics and secondly, the concentration depen-
dence of cytidine-induced inhibition of Na+-dependent
uridine uptake (Figure 1A,B). Cytidine inhibited Na+-
dependent uridine uptake with an IC50 of 4.5 µM
(Figure 1B). With the substrate/inhibitor concentration
ratio used (1 to 100 µM), this yielded an almost iden-
tical Ki value (4.38 µM). Moreover, Ki was very close
to the apparent Km (3.1 µM) derived from the uptake
kinetics shown in Figure 1A. This demonstrated that
the hCNT1-CHO clone was a suitable cell model for
the analysis of hCNT1 substrate selectivity. 
The interaction between hCNT1 and nucleosides of
pharmacological relevance was then assessed in
hCNT1-CHO cells by monitoring the inhibition of
1 µM Na+-dependent uridine uptake triggered by a
panel of nucleosides used at high concentrations
(Figure 2). Two naturally occurring pyrimidine nucleo-
sides, cytidine and thymidine, significantly inhibited
uridine transport when used at a concentration of
100 µM (P<0.001), far above their known apparent
Km for the transporter. Gemcitabine and 5′-DFUR, two
pyrimidine nucleoside derivatives used in anticancer
therapy, when assayed at the same concentration
(100 µM) also inhibited transport, although inhibition
by 5′-DFUR was markedly lower than that exerted by
the other nucleosides. The antiviral drugs AZT, d4T,
ddC and 3TC were used at a concentration of 5 mM to
determine whether any interaction with the transporter
occurs, even if of low affinity. AZT, d4T and ddC, but
not 3TC, significantly inhibited hCNT1-mediated
uridine uptake (AZT, P<0.001; d4T and ddC, P<0.05),
AZT being the most effective. The concentration-
dependence of this inhibitory action on hCNT1
function was then analysed for AZT, d4T and ddC
(Figure 3). Whereas AZT almost completely abolished
hCNT-1-mediated transport at the highest concentra-
tion used (85% inhibition at 10 mM) (Figure 3A), d4T
and ddC, when used at the maximal concentrations
allowed by their solubility limit (20 mM) exhibited
approximately 80% inhibition of the Na+-dependent
uridine uptake (Figure 3B,C).
Inhibition of hCNT1-mediated substrate transloca-
tion is not necessarily associated with transportability.
To determine whether these three antiviral nucleoside
derivatives are indeed translocated by hCNT1, nucleo-
side driven Na+-inward currents were monitored in
different X. laevis oocytes expressing hCNT1, using
the two-electrode voltage-clamp technique. Water-
injected oocytes did not show any nucleoside-driven
Na+-inward current (data not shown). Figure 4 shows
representative electrophysiological records of currents
generated by the naturally occurring nucleoside uridine
and selected nucleoside derivatives at a clamped poten-
tial of –50 mV. Oocytes were continuously perfused
with Na+ buffer and a baseline current, which corre-
sponds to the Na+-leak current in the absence of
substrate, was recorded. Addition of 0.5 mM uridine
Antiviral Therapy 9:6 995
Interaction of nucleoside-derived drugs with hCNT1
Figure 1. Interaction of cytidine with recombinant hCNT1 expressed in CHO-K1 cells
(A) Concentration-dependence of Na+-dependent cytidine uptake by recombinant hCNT1. The inset shows the Eadie–Hoftsee plot (v versus v/s) that was used for the
estimation of the apparent Km value. Data are given as absolute uptake rates (pmol cytidine/mg protein/90 sec). Results are the mean ±SEM of four independent
experiments. (B) Cytidine inhibition of Na+-dependent uridine uptake by recombinant hCNT1. The uptake of 1 µM [3H] uridine was measured over 90 sec in the pres-
ence of increasing concentrations of cytidine. Results are shown as percentage of control (absence of inhibitor) values and are expressed as the mean ±SEM of three
independent experiments.
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evoked an inward current of ~150 nA (Figure 4A). The
intensity of these Na+-inward currents varied among
oocytes (Figure 4A–C) reflecting, as for other trans-
porters, different hCNT1 expression levels. Washing
out with Na+ buffer after perfusion of the nucleoside
returned the current to the original baseline (not
shown), as previously reported [22], but routinely,
especially when different substrates were going to be
perfused in a single oocyte, Na+-free solution was used
for a fast removal of the Na+ and substrate. Inward
current and the baseline current therefore disappeared
when the oocyte was washed out with Na+-free buffer.
Addition of Na+ buffer returned the current to baseline
levels. AZT (Figure 4A) and d4T (Figure 4B), but not
ddC (Figure 4C), elicited substrate-induced Na+-
inward currents, thus demonstrating that AZT and
d4T-mediated inhibition of Na+-dependent uridine
uptake is indeed associated with transportability.
Nervertheless, ddC inhibited the Na+-leak and uridine-
induced currents (Figure 4C), indicating that although
this nucleoside derivative is able to bind the trans-
porter, it is not translocated. The apparent inhibition
constant for ddC obtained by inhibition of the Na+-
leak current was 5.5 mM. 
The voltage-dependence of the hCNT1-mediated
uptake of AZT and d4T was then determined by
measuring substrate-driven Na+-inward currents at
different membrane potentials. The derived Imax and
K0.5 values for AZT are shown in Figure 5. Imax was
similarly voltage-dependent for both uridine and AZT
(Figure 5A), although maximal current for the drug
P Cano-Soldado et al.
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Figure 2. Inhibition of hCNT1-mediated uridine uptake by
nucleosides and nucleoside analogues in CHO-K1 cells
The Na+-dependent uptake of 1 µM [3H] uridine was measured over a 90 sec
incubation time, either in the absence (Ctrl) or in the presence of high concen-
trations of competing non-radiactive nucleosides. Cytidine (Cyt), thymidine
(Thy), gemcitabine (Gem) and 5′-DFUR were used at 100 µM, whereas AZT, d4T,
ddC and 3TC were all used at 5 mM. Data are expressed as percentage of
uptake versus control (absence of inhibitor) value. Results are expressed as the
mean ±SEM of three independent experiments. Statistical significance was
assessed using Student’s t-test: ctrl versus inhibitor (*P<0.05; ***P<0.001).
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Figure 3. Concentration-dependent inhibition of recombi-
nant hCNT1-mediated uridine uptake by antiviral drugs 
The Na+-dependent uptake of 1 µM [3H] uridine by recombinant hCNT1
expressed in CHO-K1 cells was measured over a 90 sec incubation time in the
presence of increasing concentrations of (A) AZT, (B) ddC and (C) d4T. Results
are shown as the percentage of the hCNT1-mediated uptake rates measured in
the absence of inhibitor and are expressed as the mean ±SEM of three indepen-
dent experiments.
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was markedly higher (around twofold) than that of
uridine. Similar behaviour was observed when d4T
was used as substrate, although Imax values were three-
to fivefold higher than those measured with the natu-
rally occurring nucleoside uridine (not shown). K0.5 for
AZT was voltage-independent at physiological and
hyperpolarizing membrane potentials (1.1 mM at
–50 mV, Figure 5B), as it was for d4T (15.6 mM at
–50 mV, data not shown). 
The apparent Km derived from these kinetic studies
as well as the IC50 values obtained from the cross-
inhibition experiments (depicted in Figures 2 and 3) are
shown in Table 1. For a better comparison between
nucleosides, their chemical structures are also shown
(Figure 6). Naturally occurring nucleosides and the
two pyrimidine nucleoside derivatives used in anti-
cancer therapy, gemcitabine and 5′-DFUR, showed
IC50 and apparent Km values in the low-mid µM range.
Constants for AZT reached 1 mM, whereas d4T
kinetic values ranged from 4–15 mM. ddC, although
not being transported, had similar IC50 values to those
of d4T. 
All these nucleosides and derivatives differ in a
number of structural features, but a significant differ-
ence between those that are efficiently transported and
the antiviral nucleosides studied here is the lack of the
hydroxyl group in the 3′ position of the sugar (Figure
6). To ascertain whether this is a key structural deter-
minant for hCNT1 recognition, we compared the
interaction of thymidine and 3′-deoxythymidine with
hCNT1. Indeed, the lack of the hydroxyl group in the
3′ position of the deoxyribose is enough to dramatically
increase the IC50 value derived from the cross-inhibition
experiments shown in Figure 7. IC50 values were 12 µM
and 737 µM for thymidine and 3′-deoxythymidine,
respectively. Similar cross-inhibition experiments were
then performed using cytidine and its corresponding
ribose-modified nucleosides (data not shown). IC50
values derived from these studies revealed that cytidine
and 2′-deoxycytidine exerted a similar effect on uridine
uptake (IC50 values of 4.5 µM vs 8.6 µM, respectively),
whereas, as shown earlier (Figures 3 and Table 1), 2′,3′-
dideoxycytidine (ddC) inhibited uridine transport with
an IC50 value of nearly 6 mM.
Antiviral Therapy 9:6 997
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Figure 4. Na+ currents evoked in oocytes expressing hCNT1 by uridine and nucleoside-derivatives with antiviral properties 
Each panel corresponds to a different oocyte. Oocytes were held at –50 mV and continuously perfused with Na+ buffer in the absence of substrate (blank box). The
current registered under that condition corresponds to the Na+-leak current. Addition of uridine or antiviral drugs is indicated by an arrow. After perfusion with each
nucleoside, oocytes were washed out in Na+-free medium (black box). Both AZT and d4T induced Na+-inward current indicating that they are transported (A) and (B).
ddC did not induce inward currents, even when added at higher concentrations (up to 5 mM) than those shown in this panel (not shown). Nevertheless, ddC reduced
the Na+-leak current and the simultaneous perfusion of uridine and ddC completely inhibited uridine-induced inward current at 2.5 mM (C), which indicates that
although it is not transported, it is able to bind the transporter.
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Discussion
This study demonstrates that the so-called ‘high-
affinity’ pyrimidine-preferring nucleoside transporter
CNT1 is not in fact a broad-selectivity carrier for
pyrimidine-derived drugs. hCNT1 is responsible for
the translocation of selected anticancer drugs, thus
conferring chemosensitivity to those cells expressing
the transporter [7,8]. However, among the selected
antiviral drugs used in this study none appears to
interact with high affinity with hCNT1. This was
evident even when the concentrations tested were
above those expected in vivo.
Although AZT and d4T are recognized by hCNT1
with relatively low affinity, they appear to be translo-
cated with higher Vmax values than those found for
naturally occurring nucleosides and selected fluoro-
pyrimidines. We have recently demonstrated that Imax
values for cytidine and its analogue gemcitabine are
comparatively low and independent of membrane
potential, thus suggesting decreased constant rates for
the fully loaded nucleoside/Na+/transporter complexes
[22]. This occurs despite their apparent high binding
affinity for the carrier protein [6,22]. These two nucle-
osides carry an NH2 group at the 4 position of the
pyrimidine ring, whereas other nucleosides that show
voltage-dependence of their Imax values, including the
antiviral drugs assayed here, carry an O in that posi-
tion. Little is known about the structural determinants
of the pyrimidine ring necessary for substrate recogni-
tion and translocation. However, when measuring
P Cano-Soldado et al.
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Figure 5. K0.5 and Imax for AZT as a function of membrane
potential
Experiments were routinely performed in hCNT1-expressing oocytes 3 days after
cRNA injection. K0.5 and Imax for AZT were obtained at every membrane potential
by fitting the steady-state currents obtained at seven different concentrations
(from 50–5000 µM) to the equation described in Materials and methods. A
representative experiment using a single oocyte expressing hCNT1 is shown. The
error bars correspond to fitting error. (A) Imax/V curve. Maximal current for
uridine was obtained using a saturating uridine concentration (0.5 mM). At each
membrane potential, Imax for AZT was 1.5- to twofold higher than that for
uridine and increased with more negative potentials from –360 nA at –50 mV to
–560 nA at –150 mV. (B) K0.5/V curve. K0.5 values were comparable at each
membrane potential between –50 (1160 ±29 µM) and –150 (906 ±94 µM) mV.
Similar results were obtained with oocytes from five different frog donors.
(C) Fit of the data used to obtain Imax and K0.5 of AZT in Figure 5A and B.
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Table 1. Kinetic constants of hCNT1 interaction for selected
naturally occurring nucleosides and nucleoside analogues
used in anticancer and antiviral therapies 
IC50, µM Km, µM
Cytidine 4.5 ±0.3 3.1 ±1.4
Thymidine 12.55 ±3.3 ND
AZT 1004 ±260 963 ±330
d4T 4525 ±521 15 600 ±4700
ddC 5730 ±384 NT
3TC >>20 000 NT
Gemcitabine ND 17 ±5
5’-DFUR ND 209 ±135
Apparent Km and IC50 values for nucleosides, antiviral and anticancer drugs. IC50
values were obtained from experiments depicted in Figures 1, 3 and 7.
Apparent Km values for AZT and d4T were calculated by fitting the data
obtained using the two-electrode voltage-clamp technique in X. laevis oocytes
expressing hCNT1. Apparent Km values for gemcitabine and 5′-DFUR have been
taken from Lostao et al. (2000) [6] and Mata et al. (2001) [7]. The apparent Km
value for cytidine was calculated from data shown in Figure 1A. For a better
understanding of putative structural features conferring nucleoside interaction
with hCNT1, the chemical structures of all compounds used in this study are
also shown (Figure 6). Values are expressed as mean ±SD. ND, not determined;
NT, not transported.
substrate selectivity of the rat orthologue of CNT1 by
electrophysiological techniques at a single membrane
potential, it has been shown that a change in the N
from the 5 to 6 position of the azacytidine molecule
results in a loss of transportability [23]. 
Moreover, in a recent contribution analysing the
uridine-binding motifs of hCNT1, it has been shown
that N at position 3 also contributes to substrate
binding [24]. Our previous data [22] and those
presented here for the antiviral drugs, suggest that an N
or an O at position 4 would probably modify the voltage
dependence of the Imax values, without significantly modi-
fying substrate recognition itself. Nevertheless, since
nucleobases do not interact with CNT transporters it is
likely that substrate recognition relies mostly upon the
ribose ring structure, as recently reported for the
Toxoplasma gondii high-affinity nucleoside transporter
TgAT2 [25]. Indeed, a primary role for the ribose in
determining substrate transportability is supported by
the fact that all antiviral drugs assayed here, which are
either not transported or poorly transported by hCNT1,
lack the 3′ hydroxyl group of the sugar. Thus, this posi-
tion appears to be a key structural determinant for
nucleoside recognition by the human orthologue of
CNT1, irrespective of whether the pyrimidine nucleo-
side incorporates a ribose or a 2′-deoxyribose. Our
comparative analysis of the interactions of thymidine, 3′-
deoxythymidine, cytidine, 2′-deoxycytidine and ddC
with hCNT1 supports this hypothesis. This agrees with
a recent contribution by Cass and colleagues in which
the uridine-binding motifs recognized by the human
orthologue of CNT1 were analysed by measuring cross-
inhibition of uridine uptake by a set of uridine
analogues [24].
The evidence that slight changes in nucleoside struc-
ture may determine such a dramatic shift in substrate
recognition and transportability may be physiologi-
cally and pharmacologically relevant. Nucleosides and
most of their analogues are absorbed in the intestine
and efficiently reabsorbed in the renal tubule, due to
the polarized localization of nucleoside transporters
CNT proteins are located at the apical side, whereas
the equilibrative nucleoside carriers (SLC29) have been
found at the basolateral side of epithelial cells
[9,11,12,26]. The exclusion of certain pyrimidine
nucleoside derivatives from recognition by the high-
affinity, pyrimidine-preferring nucleoside transporter
hCNT1 would compromise their disposition unless
alternative carriers recognize these compounds. ENT
transporters may be candidates for this physiological
role. Although interaction of AZT with hENT1 has
been described by cross-inhibition studies, this
analogue seems to be a substrate of the hENT2 isoform
[27]. ddC also appears to be recognized by ENT1 and
ENT2, although the reported apparent Km value for
ENT1-mediated uptake was 22 mM [27]. Moreover,
Antiviral Therapy 9:6 999
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Figure 6. Structures of naturally occurring nucleosides and nucleoside analogues used in anticancer and antiviral therapies 
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AZT and ddC are also substrates of the human
concentrative nucleoside transporter hCNT3, but
probably with low affinity, as reported here for
hCNT1 [28]. Carriers belonging to the SLC22 family,
mostly organic anion transporters (OATs) and, to a
lesser extent, organic cation transporters (OCTs), have
been implicated in the uptake of some nucleoside deriv-
atives, such as AZT [29–31]. High affinity transport of
AZT has been reported for OAT1, OAT2, OAT3 and
OAT4, with apparent Km values in the 20–150 µM
range [31–33]. Whereas OAT1, OAT2 and OAT3 show
mainly basolateral localization in renal epithelial cells;
OAT4 is located at the apical side [34]. However, their
exact role in AZT disposition is somewhat uncertain,
because they are all anion exchangers with as yet unde-
fined stoichiometry [34]. It has been suggested that
exchange involves one organic anion/one dicarboxylate,
and, as for OAT3, it may be indirectly coupled to the
Na+ gradient [35]. Moreover, although OAT4 is the
only member of this family located at the apical side of
renal epithelial cells, it is not yet known whether this
isoform is expressed in enterocytes [36]. Thus, the
exact driving force for AZT uptake remains to be fully
elucidated and it also remains to be seen which would
be suitable high-affinity carriers responsible for the
apical uptake of this and other antiviral drugs. The
apical location of hCNT1 in enterocytes would favour
the view that this transporter might play a minor role
in AZT absorption if luminal drug concentrations
reach much higher levels than in plasma. Nevertheless,
the apparent Km value for AZT is definitely far above
those concentrations encountered in humans. 
In summary, this study demonstrates that the high-
affinity nucleoside transporter hCNT1 is not in fact
a broad-selectivity pyrimidine nucleoside carrier,
particularly for those derivatives lacking a hydroxyl
group at the 3′ position of the ribose ring, as in the
case of selected inhibitors of HIV-1 reverse transcrip-
tase. It is also apparent that very slight changes in
substrate structure provoke a dramatic shift in selec-
tivity. Thus, hCNT1 is probably not a suitable target
to improve drug therapy with nucleoside HIV reverse
transcriptase inhibitors. Hence, the role of other trans-
porters, such as OATs, in antiviral drug targeting
requires further research. 
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